Business Wire

Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare

Share

Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’s scientists, creating a unique innovation ecosystem that is aimed at advancing scientific breakthroughs and enhancing research success.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204100180/en/

From left upper row, to right: Marc Soriano, R&D Project Portfolio and Partnership, Lidia Martín, General Manager of Almirall Iberia, Antonio Gallardo, Jorge Gallardo, Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, Meritxell Granell, Director of Institutional Relations, Raquel Yotti, PERTE Commissioner for Vanguard Health, Olga Pané, Consellera de Salut, Lourdes Borrell, Mayoress of Sant Feliu de Llobregat, Salvador Illa, President of the Generalitat de Catalunya, Carlos Gallardo, CEO and President of Almirall, Juan Cruz Cigudosa, Secretary of State for Science, Innovation and Universities, Núria Montserrat, Consellera de Recerca i Universitats, and Jaume Baró, Secretary for Business and Competitiveness of the Department of Business and Employment. (Photo: Business Wire)

The Hive builds on Almirall's open innovation centre, which began operations in 2023 with collaborations with two life science companies. The arrival of two new joiners announced today contribute to the creation of this unique collaboration ecosystem, following the initial partnerships with ZeClinics, a Contract Research Organization (CRO) specializing in genetics research using zebrafish as a model organism, and Centrient Pharmaceuticals, a global leader in sustainable biosynthetic pharmaceutical products.

The initiative was launched today as part of Almirall's 80th anniversary celebrations, bringing together health authorities, representatives from associations, entities, and institutions with whom Almirall closely collaborates to deliver against its commitment to patients, innovation, and the advancement of healthcare. The new joiners at The Hive include ADmit Therapeutics a company focused on the early detection of Alzheimer’s and other neurodegenerative diseases through technology that combines epigenetic and clinical data using machine learning. The most recent addition is Microomics a company specializing in metagenomic analysis using new DNA sequencing technologies (NGS).

"At Almirall, we bring together scientific experts from different disciplines in a collaborative environment as we see the transformative power collaboration has to push the boundaries of science and drive the development of novel solutions. An open innovation ecosystem that fosters this collaboration lays an exceptional foundation for breakthroughs in both scientific discovery and product development. We are proud to lead the way with The Hive, a unique initiative designed to advance science and innovation. By working together, we can address critical unmet needs and deliver meaningful progress in healthcare, ensuring that our innovations make a tangible difference in the lives of patients and their families", stated Dr. Karl Ziegelbauer, Almirall’s Chief Scientific Officer.

80 years of innovation and commitment to patients

Almirall is celebrating its 80th anniversary, marking eight decades of commitment to patients, innovation, and healthcare advancement. To commemorate this milestone, the company hosted an institutional event at its R&D centre in Barcelona, Spain. The event brought together health authorities, partners and institutional representatives, including the President of the Generalitat de Catalunya, Salvador Illa, Juan Cruz Cigudosa, Secretary of State for Science, Innovation, and Universities, María José Alonso, professor of Pharmacy and Pharmaceutical Technology at the University of Santiago de Compostela (USC), and Lourdes Borrell, Mayor of Sant Feliu de Llobregat.

Professor María José Alonso congratulated Almirall for its 80 decades “preserving the value of science and its transfer to industry in the best way, contributing to development and well-being, and elevating scientific value in the development of the Spanish innovative ecosystem, fostering a brighter future for all”.

Almirall was founded in Spain in 1944 with the purpose of giving people access to impactful medicines, a goal that continues to guide the company in its ambition as a leading medical dermatology. Almirall´s heritage, its deep scientific expertise, and the strong partnerships with the dermatology community worldwide are the foundation for its broad portfolio of dermatological treatments. Grounded in science and driven by innovation, the company continuously advances the understanding of skin diseases and provides solutions for even the most complex conditions. Based on this dedication, Almirall has become a leader in medical dermatology in Europe, with a strong portfolio of more than 50 products across different modalities, including topical, systemic, and biologics.

The company has invested 1 billion Euros in R&D in medical dermatology in the last decade which represents a continuous investment of over 12% of its annual net sales in R&D. This investment supports all phases of research conducted at its R&D centre – from discovery to late-stage clinical testing. Almirall’s close partnership with patients and dermatologists positions the company as a trusted and reliable partner, as it constantly focuses on understanding their needs to translate these into innovative solutions, helping improve people's lives both physically and emotionally.

Carlos Gallardo, Chairman and CEO of Almirall: "Celebrating 80 years is a testament to Almirall’s enduring commitment to innovation and patient care. Our journey has been driven by a profound dedication to improving patients' lives and providing meaningful treatments. As a family-owned company, we think in generations, and have consistently prioritized innovation in medical dermatology, investing over 1 billion Euros in R&D in this area over the last decade. We are grateful for the dedication of our teams across the company, and our partners and collaborators that enable us to help so many patients, every day. Our leading capabilities in skin biology and product development will continue to be a cornerstone of our mission, ensuring our sustained focus on science and innovation to deliver healthcare solutions to patients and the medical community."

About Almirall

Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.

Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.

For more information, please visit https://www.almirall.com/

Legal notice:

This document includes only summary information and is not intended to be exhaustive. The facts, figures, and opinions contained in this document, in addition to the historical ones, are "forward-looking statements." These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals, or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204100180/en/

Contacts

Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173

Investor Relations
investors@almirall.com
Phone: (+34) 93 291 30 87

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avinor Selects Thales to Deploy Norway’s Next-Generation Nationwide Unmanned Traffic Management System9.12.2024 09:00:00 CET | Press Release

This strategic partnership with Avinor, the Norwegian air navigation service provider and airport operator, will enable the deployment of Norway’s next-generation nationwide Unmanned Traffic Management system. This collaboration represents a major step forward in Norway’s airspace management, combining innovation with strict regulatory compliance. It also signifies a key milestone for Thales in the integration of AstraUTM, a recently acquired leader in cutting-edge UTM software development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209180613/en/ Drones flying in Norway, image generated by AdobeFireFly, December 2024 (Photo: Thales) With its newly released product Topsky - UAS powered by AstraUTM, Thales will provide a safe and scalable digital platform for automated UTM and future AAM (Advanced Airspace Mobility). This system will efficiently manage air traffic in the vicinity of airports and metropolitan, suburban,

Avanza Fonder utser Northern Trust till leverantör av Integrated Trading Solutions9.12.2024 09:00:00 CET | Pressmeddelande

Northern Trust (Nasdaq: NTRS) meddelade idag att dess outsourcade tradingfunktion Integrated Trading Solutions (ITS) stödjer Avanza Fonder, ett Stockholmsbaserat fondbolag som tillhandahåller tjänster för privatkunder. Avanza Fonder grundades 2006 och är ett helägt dotterbolag till Avanza Bank Holding AB (publ). Fondbolaget förvaltar både egna fonder och fonder i samarbete med andra förvaltare. Northern Trust kommer att tillhandahålla outsourced trading för Avanza Fonders indexfonder Global, Emerging Market, European samt US equity. Gerard Walsh, global chef för Client Solutions Banking & Markets, på Northern Trust, säger: ”Vi är glada över att arbeta med Avanza Fonder, en ledande fondförvaltare i Norden, för att stödja dem över hela trading processen genom en integrerad front-middle- och backoffice-lösning. Våra skräddarsydda tjänster kommer att hjälpa Avanza Fonder att navigera i pågående globala marknadsutmaningar och göra det möjligt för dem att fokusera på att förvalta de tillgång

Kapacity.io Acquired by U.S.-based EnergyHub to Accelerate Demand-Side Flexibility in Europe9.12.2024 07:30:00 CET | Press Release

Kapacity.io, a European leader in heat pump optimization and flexibility, has been acquired by EnergyHub, North America's largest provider of residential flexibility solutions. Backed by EnergyHub’s resources and experience, Kapacity.io will continue to focus on expanding partnerships with electricity retailers and heat pump manufacturers to unlock the benefits of residential flexibility for consumers. EnergyHub’s distributed energy resource management system (DERMS) manages more than 1.5 million distributed energy resources (DERs) across over 100 utility programs in North America. Kapacity.io helps retailers optimize the energy consumption of heat pumps on dynamic tariffs and other flexibility offerings and provides congestion management and grid balancing services to distribution system operators (DSOs) and transmission system operators (TSOs), all while helping customers save money without sacrificing comfort. “This partnership opens exciting new avenues for our technology,” said Ja

FPT and RWE Sign 5-Year Master Service Agreement to Drive Innovation and Sustainability9.12.2024 03:30:00 CET | Press Release

FPT has signed a five-year Master Service Agreement (MSA) with RWE, further strengthening the longstanding partnership between the two companies. The agreement aims to advance technological innovation, operational excellence, and sustainable growth, supporting RWE’s ambitious initiatives in IT/OT convergence, renewable energy, and data-driven solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241208877842/en/ The signing ceremony took place in Essen, Germany, with the participation of Ms. Katja van Doren, Member of the Executive Board of RWE AG (L), Mdm. Chu Thi Thanh Ha, FPT Software Chairwoman (R), and senior leaders of both companies. (Photo: Business Wire) The signing ceremony in Essen, Germany, marks the beginning of an enhanced collaboration where FPT will provide a robust offshore utilization strategy through its Offshore Delivery Center. This will enable cost-effective, scalable solutions tailored to RWE’s evo

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update8.12.2024 18:52:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first and only approved CRISPR/Cas9 gene-edited therapy. The results, presented at the American Society of Hematology (ASH) Annual Meeting and Exposition, continue to demonstrate the transformative, durable clinical benefits of CASGEVY. The longest follow up for both SCD and TDT patients now extends more than 5 years, with a median of 33.2 months and 38.1 months, respectively. “These comprehensive data provide additional evidence of the benefits of eradicating transfusion requirements for people with transfusion-dependent beta thalassemia and vaso-occlusive crises for those with sickle cell disease,” said Franco Locatelli, M.D., Ph.D., Professor of Pediatrics at the Catholic University of the Sacred Heartof Rome, Director of t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye